Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

RARE PHOTOS: Why this analyst feels it s time to short embecta - The Real Truth

Despite being a market leader in insulin pen needles and syringes, Embecta Corp (NASDAQ:EMBC) may face challenges ahead, since the markets are already mature and the company has not diversified, according to BofA Securities.

The Embecta Analyst: Travis Steed initiated coverage of Embecta with an Underperform rating and a price target of $25.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.